Clinical Trials
8 trialsNCT00573378 2023-01-25
Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia
University of Michigan Rogel Cancer Center
Phase 2 Terminated
NCT02982720 2022-02-16
Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron
Hoosier Cancer Research Network
Phase 2 Terminated
NCT00037882 2018-11-01
PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of Roferon Or Intron
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01866553 2018-10-12
Nilotinib Plus Pegylated Interferon-α2b in CML
Amsterdam UMC, location VUmc
Phase 2 Terminated
NCT00415857 2018-08-21
Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00090870 2018-07-12
PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer
Medical University of South Carolina
Phase 2 Terminated
NCT00467077 2017-03-17
Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer
California Cancer Consortium
Phase 2 Terminated
NCT00511121 2007-08-03
Study of the Combination of a Tyrosine Kinase Inhibitor (STI571) and a Pegylated Human Recombinant Interferon alfa2b (PEGINTRON)
University of Bologna
Phase 2 Terminated